Dementia resulting from AD is associated with vascular function decline and involves a
pro-inflammatory state. In our Phase 1 trial, Lomecel-B treatment met the primary safety
endpoint, with no safety concerns, and showed potential to improve clinical assessments.
Mechanistically, Lomecel-B treated subjects had higher serum concentrations of pro-vascular
and anti-inflammatory biomarkers relative to placebo. This trial builds upon those
preliminary Phase 1 results, and is designed to evaluate the safety profile of multiple
infusions of Lomecel-B, and to investigate provisional efficacy of single dosing versus
multiple dosing of Lomecel-B on cognitive function and biomarkers in AD subjects.